2,5-Dimethoxy-4-methylamphetamine (DOM), a neuropharmacological examination.
D000661:Amphetamine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D001923:Brain Chemistry / Q000187:drug effects; D001966:Bromine / Q000494:pharmacology; D002415:Cats / Q000502:physiology*; D002746:Chlorpromazine / Q000494:pharmacology; D003533:Cyproheptadine / Q000494:pharmacology; D004027:Diencephalon / Q000187:drug effects; D004155:Diphenhydramine / Q000494:pharmacology; D004569:Electroencephalography; D004594:Electrophysiology; D010134:Fenclonine / Q000494:pharmacology; D006213:Hallucinogens / Q000494:pharmacology*; D008238:Lysergic Acid Diethylamide / Q000494:pharmacology; D008526:Medulla Oblongata / Q000032:analysis / Q000378:metabolism; D008738:Methyl Ethers / Q000494:pharmacology; D008781:Methyltyrosines / Q000494:pharmacology; D008784:Methysergide / Q000494:pharmacology; D009638:Norepinephrine / Q000032:analysis; D010643:Phenoxybenzamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D012110:Reserpine / Q000494:pharmacology; D012154:Reticular Formation / Q000187:drug effects; D012701:Serotonin / Q000032:analysis; D013618:Tachyphylaxis / Q000187:drug effects; D014309:Tripelennamine / Q000494:pharmacology
D006213:Hallucinogens; D008738:Methyl Ethers; D008781:Methyltyrosines; D010643:Phenoxybenzamine; D003533:Cyproheptadine; D012701:Serotonin; D014309:Tripelennamine; D001285:Atropine; D012110:Reserpine; D004155:Diphenhydramine; D008238:Lysergic Acid Diethylamide; D011433:Propranolol; D000661:Amphetamine; D010134:Fenclonine; D001966:Bromine; D002746:Chlorpromazine; D009638:Norepinephrine; D008784:Methysergide